Mitsuhiro Matsuo Selected Research

Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)

2/2006

Activation of MEK/ERK and PI3K/Akt pathways by fibronectin requires integrin alphav-mediated ADAM activity in hepatocellular carcinoma: a novel functional target for gefitinib.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Mitsuhiro Matsuo Research Topics

Disease

6	Neoplasms (Cancer) 08/2017 - 05/2003
4	Neoplasm Metastasis (Metastasis) 07/2008 - 05/2003
2	Hypertension (High Blood Pressure) 02/2020 - 08/2019
2	Drug Resistant Epilepsy 07/2015 - 07/2012
2	Hepatocellular Carcinoma (Hepatoma) 02/2006 - 06/2003
1	Ischemic Stroke 01/2023
1	Heart Failure 01/2023
1	Chronic Pain 01/2022
1	Sleep Wake Disorders 01/2022
1	Pain (Aches) 01/2022
1	Tachycardia (Tachyarrhythmias) 02/2020
1	Headache (Headaches) 02/2020
1	Miosis 02/2020
1	Sarcopenia 06/2019
1	Malnutrition (Nutritional Deficiencies) 06/2019
1	Diabetes Mellitus 08/2017
1	Peripheral Nervous System Diseases (PNS Diseases) 08/2017
1	Dyslipidemias (Dyslipidemia) 08/2017
1	Partial Epilepsies (Epilepsy, Partial) 07/2015
1	Seizures (Absence Seizure) 07/2015
1	Carcinoma (Carcinomatosis) 02/2013
1	Clinical Deterioration 01/2012
1	Hypersensitivity (Allergy) 01/2012
1	Melanoma (Melanoma, Malignant) 07/2008
1	Prostatic Neoplasms (Prostate Cancer) 07/2007
1	Dystonia (Limb Dystonia) 11/2006

Drug/Important Bio-Agent (IBA)

2	Cholinesterases (Cholinesterase)IBA 02/2020 - 06/2019
2	ErbB Receptors (EGF Receptor)IBA 02/2006 - 06/2003
2	Gefitinib (Iressa)FDA Link 02/2006 - 06/2003
2	Tyrosine Kinase InhibitorsIBA 02/2006 - 06/2003
1	omega-Chloroacetophenone (Mace)IBA 01/2023
1	suvorexantIBA 01/2022
1	Mirtazapine (Rexer)FDA LinkGeneric 01/2022
1	Antidepressive Agents (Antidepressants)IBA 01/2022
1	Cholinergic Agents (Cholinergics)IBA 02/2020
1	distigmine (distigmine bromide)IBA 02/2020
1	Rivastigmine (Exelon)FDA LinkGeneric 02/2020
1	Clopidogrel (Plavix)FDA Link 08/2017
1	Paclitaxel (Taxol)FDA LinkGeneric 08/2017
1	Levetiracetam (Keppra)FDA LinkGeneric 07/2015
1	MicroRNAs (MicroRNA)IBA 02/2013
1	Topiramate (Topamax)FDA LinkGeneric 07/2012
1	Prednisolone (Predate)FDA LinkGeneric 01/2012
1	Lamotrigine (Lamictal)FDA LinkGeneric 01/2012
1	Ketamine FDA LinkGeneric 01/2012
1	Midazolam (Versed)FDA LinkGeneric 01/2012
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 07/2008
1	Neuregulin-1 (Neuregulin 1)IBA 07/2008
1	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 07/2008
1	LigandsIBA 07/2008
1	histidine-rich proteinsIBA 07/2008
1	AntibodiesIBA 07/2007
1	Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor)IBA 07/2007
1	CurcuminIBA 06/2007
1	BerberineIBA 06/2007
1	Guanosine Triphosphate (GTP)IBA 11/2006
1	Fibronectins (Fibronectin)IBA 02/2006
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 02/2006
1	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 02/2006
1	Integrin alphaVIBA 02/2006
1	N- hydroxy- 5- ethoxymethyloxy- 2- methyl- 4- (4- phenoxybenzoyl)aminopentanamideIBA 05/2003
1	Messenger RNA (mRNA)IBA 05/2003
1	Peptide Hydrolases (Proteases)FDA Link 05/2003
1	Urokinase-Type Plasminogen Activator (Urokinase)FDA Link 05/2003
1	Matrix Metalloproteinases (MMPs)IBA 05/2003
1	RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA 05/2003

Therapy/Procedure

2	Therapeutics 08/2019 - 07/2015
1	Ligation 01/2022